Ernexa Therapeutics Statistics
Total Valuation
ERNA has a market cap or net worth of $11.21 million. The enterprise value is $12.18 million.
Important Dates
The next estimated earnings date is Friday, June 13, 2025, after market close.
| Earnings Date | Jun 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ERNA has 62.36 million shares outstanding. The number of shares has increased by 376.06% in one year.
| Current Share Class | 62.36M |
| Shares Outstanding | 62.36M |
| Shares Change (YoY) | +376.06% |
| Shares Change (QoQ) | +39.11% |
| Owned by Insiders (%) | 62.14% |
| Owned by Institutions (%) | 4.42% |
| Float | 17.40M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 8.62 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 22.77 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.21
| Current Ratio | 0.21 |
| Quick Ratio | 0.20 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.38 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -32.42% |
| Return on Invested Capital (ROIC) | -43.30% |
| Return on Capital Employed (ROCE) | 263.86% |
| Revenue Per Employee | $89,167 |
| Profits Per Employee | -$7.69M |
| Employee Count | 6 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, ERNA has paid $34,000 in taxes.
| Income Tax | 34,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -90.54% in the last 52 weeks. The beta is 7.12, so ERNA's price volatility has been higher than the market average.
| Beta (5Y) | 7.12 |
| 52-Week Price Change | -90.54% |
| 50-Day Moving Average | 0.21 |
| 200-Day Moving Average | 0.62 |
| Relative Strength Index (RSI) | 35.16 |
| Average Volume (20 Days) | 429,204 |
Short Selling Information
The latest short interest is 127,421, so 0.20% of the outstanding shares have been sold short.
| Short Interest | 127,421 |
| Short Previous Month | 104,315 |
| Short % of Shares Out | 0.20% |
| Short % of Float | 0.73% |
| Short Ratio (days to cover) | 0.70 |
Income Statement
In the last 12 months, ERNA had revenue of $535,000 and -$46.11 million in losses. Loss per share was -$1.80.
| Revenue | 535,000 |
| Gross Profit | 500,000 |
| Operating Income | -14.19M |
| Pretax Income | -22.90M |
| Net Income | -46.11M |
| EBITDA | -14.08M |
| EBIT | -14.19M |
| Loss Per Share | -$1.80 |
Full Income StatementBalance Sheet
The company has $1.92 million in cash and $2.88 million in debt, giving a net cash position of -$964,000 or -$0.02 per share.
| Cash & Cash Equivalents | 1.92M |
| Total Debt | 2.88M |
| Net Cash | -964,000 |
| Net Cash Per Share | -$0.02 |
| Equity (Book Value) | -5.95M |
| Book Value Per Share | -0.11 |
| Working Capital | -8.23M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$14.15 million and capital expenditures -$268,000, giving a free cash flow of -$14.42 million.
| Operating Cash Flow | -14.15M |
| Capital Expenditures | -268,000 |
| Free Cash Flow | -14.42M |
| FCF Per Share | -$0.23 |
Full Cash Flow StatementMargins
| Gross Margin | 93.46% |
| Operating Margin | -2,652.90% |
| Pretax Margin | -8,609.35% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |